Compare Ryanair Holdings plc (RYAAY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs State Street SPDR S&P Biotech ETF — how do they compare? Ryanair Holdings plc trades at $59.4 (market cap $29.63B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Ryanair Holdings plc pays a 1.51% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ryanair Holdings plc nearer its low. Which is the better fit depends on your goals.
| RYAAY | XBI | |
|---|---|---|
Market Cap | $29.63B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $73.82 | $164.28 |
52-Week Low | $53.24 | $86.92 |
Enterprise Value | $26.61B | — |
Dividend Yield | 1.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $59.36, down 0.25% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and attractive valuation with a P/E of 14.37. Recent news highlights a strategic AI partnership with Google Cloud and industry challenges from lower fares and fuel costs.
The outlook is balanced; analyst consensus is bullish (62.5% buy ratings), but near-term headwinds from fare pressure and geopolitical risks persist. The stock offers value based on earnings, though operational volatility and competitive dynamics require monitoring for sustained growth.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
